Arnold R Gammaitoni

6PUBLICATIONS
19CO-AUTHORS
Predictive and prognostic markersPharmacogenomicsLiquid biopsiesMajor global burdens of diseaseChild and adolescent development
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Nov 29, 2023
Fenfluramine increases survival and reduces markers of neurodegeneration in a mouse model of Dravet syndrome.

John Cha, Gregory Filatov, Steven J Smith

|Aug 06, 2023
Fenfluramine in the treatment of Dravet syndrome: Results of a third randomized, placebo-controlled clinical trial.

Joseph Sullivan, Lieven Lagae, J Helen Cross

|Oct 05, 2022
Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study.

Kelly G Knupp, Ingrid E Scheffer, Berten Ceulemans

|Jul 08, 2022
An examination of the efficacy and safety of fenfluramine in adults, children, and adolescents with Dravet syndrome in a real-world practice setting: A report from the Fenfluramine European Early Access Program.

Renzo Guerrini, Nicola Specchio, Ángel Aledo-Serrano

|Oct 22, 2021
Fenfluramine significantly reduces day-to-day seizure burden by increasing number of seizure-free days and time between seizures in patients with Dravet syndrome: A time-to-event analysis.

Joseph Sullivan, Nicola Specchio, Orrin Devinsky

|Oct 20, 2020
Fenfluramine HCl (Fintepla® ) provides long-term clinically meaningful reduction in seizure frequency: Analysis of an ongoing open-label extension study.

Joseph Sullivan, Ingrid E Scheffer, Lieven Lagae

Pageof 1

Frequent Collaborators

4 joint publications

Bradley S Galer

3 joint publications

Lieven Lagae

3 joint publications

Renzo Guerrini

2 joint publications

Nicola Specchio